Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Cardiovascular
Immunology
Neuroscience
Oncology
TNO155-SHP2 inhibitor
NCT03114319 (CTNO155X2101)
Indication
Solid tumors (single agent)
Phase 1
Phase
Patients
255
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Number of participants with adverse events
Number of participants with dose limiting toxicities
Drug: TNO155
Drug: TNO155 in combination with EGF816 (nazartinib)
Adult patients with advanced solid tumors in selected indications
Read-out
Milestone(s)
2023
Publication
TBD
References
Abbreviations
Other
81 Investor Relations | Q3 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation